Literature DB >> 2455965

T-cell recognition of pre-S regions of HBsAg can bypass nonresponse to the S region.

D R Milich1, A McLachlan, G B Thornton.   

Abstract

The objective of the studies reported herein was to identify and characterize T cell and B cell recognition sites within the pre-S regions of HBsAg/p39, and to analyze functional T-cell-B cell interactions at the level of in vivo antibody production. The results indicate: (1) several peptides within the pre-S(1) region of HBsAg were identified which can induce and elicit HBsAg/p39-specific T-cell proliferation; (2) a 10 amino acid peptide, p12-21, and the 94-117 sequence define pre-S(1)-specific T-cell recognition sites; (3) five distinct, pre-S(1)-specific antibody binding sites and 2 pre-S(2)-specific antibody binding sites were identified; (4) synthetic pre-S(1) region T-cell determinants can prime in vivo antibody production to multiple B-cell epitopes within the pre-S(2) and S regions, as well as within the pre-S(1) region; and (5) specificity of the primed T cell population can influence the specificity of the B-cell response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2455965     DOI: 10.1007/978-1-4684-5442-0_20

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Enhanced effect of DNA immunization plus in vivo electroporation with a combination of hepatitis B virus core-PreS1 and S-PreS1 plasmids.

Authors:  Hong Chen; Bo Wen; Yao Deng; Wen Wang; Xiao Yin; Jie Guan; Li Ruan; Wenjie Tan
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

Review 2.  [Hepatitis B vaccines-history, achievements, challenges, and perspectives].

Authors:  Wolfram H Gerlich
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-01-11       Impact factor: 1.513

3.  "Dual use": The anti-allergy vaccine BM32 and its HBV carrier protein.

Authors:  Wolfram H Gerlich
Journal:  EBioMedicine       Date:  2020-09-22       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.